518-18-3
Chemical Structure
(±)-Evodiamine
- CAS No.: 518-18-3
- Formula:C19H17N3O
- Molecular Weight:303.36
IUPAC Name: 14-methyl-8,13,13b,14-tetrahydroindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(7H)-one
InChIKey: TXDUTHBFYKGSAH-UHFFFAOYSA-N
SMILES: O=C1C2=CC=CC=C2N(C)C(N1CC3)C4=C3C5=CC=CC=C5N4
Biological Activity: (±)-Evodiamine is an orally active indoloquinazoline alkaloid composed of equal amounts of enantiomers, with (+)-Evodiamine exerting the primary biological functions. (±)-Evodiamine is a Top1 inhibitor and a TRPV1 receptor agonist. (±)-Evodiamine induces cell cycle arrest and apoptosis by inhibiting Top1 and disrupting Tubulin polymerization, suppresses oncogenic signaling pathways such as NF-κB and Akt, and specifically agonizes TRPV1 receptors to regulate neuropeptide release and energy metabolism. (±)-Evodiamine is used in research on traumatic brain injury, obesity, cancer, neuropathy, dry eye disease, and colitis[1][2][3][4][5][6][7][8].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(±)-Evodiamine | 99.74% | (±)-Evodiamine is an orally active indoloquinazoline alkaloid composed of equal amounts of enantiomers, with (+)-Evodiamine exerting the primary biological functions. (±)-Evodiamine is a Top1 inhibitor and a TRPV1 receptor agonist. (±)-Evodiamine induces cell cycle arrest and apoptosis by inhibiting Top1 and disrupting Tubulin polymerization, suppresses oncogenic signaling pathways such as NF-κB and Akt, and specifically agonizes TRPV1 receptors to regulate neuropeptide release and energy metabolism. (±)-Evodiamine is used in research on traumatic brain injury, obesity, cancer, neuropathy, dry eye disease, and colitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(±)-Evodiamine (Standard) | ≥98% | (±)-Evodiamine Standard is the analytical standard of (±)-Evodiamine (HY-N0114A). This product is intended for research and analytical applications. (±)-Evodiamine is an orally active indoloquinazoline alkaloid composed of equal amounts of enantiomers, with (+)-Evodiamine exerting the primary biological functions. (±)-Evodiamine is a Top1 inhibitor and a TRPV1 receptor agonist. (±)-Evodiamine induces cell cycle arrest and apoptosis by inhibiting Top1 and disrupting Tubulin polymerization, suppresses oncogenic signaling pathways such as NF-κB and Akt, and specifically agonizes TRPV1 receptors to regulate neuropeptide release and energy metabolism. (±)-Evodiamine is used in research on traumatic brain injury, obesity, cancer, neuropathy, dry eye disease, and colitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zheng H, et al. Evodiamine attenuates neurological impairment by inducing PANoptosis in microglia after severe traumatic brain injury. Pharmacological research. 2025 Dec;222:108034.
- [2]. Zhang H, et al. Combination of Berberine and Evodiamine Alleviates Obesity by Promoting Browning in 3T3-L1 Cells and High-Fat Diet-Induced Mice. Int J Mol Sci. 2025 Apr 28;26(9):4170.
- [3]. Yu Y, et al. Evodiamine impairs HIF1A histone lactylation to inhibit Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer. European journal of pharmacology. 2023 Oct 15;957:176007.
- [4]. Wu P, et al. Evodiamine attenuates chemotherapy-induced peripheral neuropathy by mediating macrophage M2 polarization and inhibiting the upregulation of the p38 MAPK-TRPV1 axis in rat dorsal root ganglia. Molecular pain. 2025;21:17448069251392037. [Content Brief]
- [5]. Li B, et al. Evodiamine Promotes Autophagy and Alleviates Oxidative Stress in Dry Eye Disease Through the p53/mTOR Pathway. Investigative ophthalmology & visual science. 2025 Mar 03;66(3):44.
- [6]. Tao X, et al. Co-administration of berberine and evodiamine: Mitigating evodiamine-induced hepatotoxicity and potentiating colitis treatment. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2025 Nov;147:157185.
- [7]. Dong G, et al. New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations. Journal of medicinal chemistry. 2012 Sep 13;55(17):7593-613. [Content Brief]
- [8]. Chen M, et al. Stereoselectivity of evodiamine enantiomers in neuroprotective activity, pharmacokinetics and the ability across the blood-brain barrier. Journal of chromatography. A. 2025 Feb 22;1743:465658. [Content Brief]
